Colgate Q2 FY27: revenue +12% YoY, PAT +4% as A&P jumps 40%, margins compress ~290bps
PAT +4.29% YoY · revenue +12.26% · margins compressing
₹1,705.79 Cr
+12.26% YoY
₹341.57 Cr
+4.29% YoY
19.77%
-1.6pp YoY
₹12.56
Colgate-Palmolive India's standalone Q2 FY27 (quarter ended September 30, 2026) revenue from operations came in at ₹1,705.79 Cr, up 12.3% YoY and 6.4% QoQ — a second straight quarter of double-digit top-line growth after Q1 FY27's 11.8%. But profit growth badly lagged: PAT of ₹341.57 Cr (EPS ₹12.56) rose just 4.3% YoY and actually slipped 0.4% QoQ from ₹343.08 Cr, with no exceptional items in either the current or year-ago quarter to distort the comparison — this is a genuine, operating-level growth-to-profit gap, not a base-effect or one-off artifact.
Q2 FY-2027 vs prior quarters
The gap sits squarely in margins: net profit margin fell to 19.8% of total income from 21.3% a year ago and 21.1% last quarter (a ~150bps YoY compression), while operating margin (EBITDA/revenue-from-operations) eased to roughly 27.8% from ~30.6% YoY and ~29.9% QoQ. The driver is advertising: A&P spend jumped 39.9% YoY and 25.0% QoQ to ₹314.82 Cr, taking A&P intensity to ~18.5% of revenue — above the ~15.8% level (up from 12-13%) management flagged on the August 2026 concall as the new normal for absorbing premiumisation-led brand investment. Employee costs also rose a faster 15.1% YoY, adding to the squeeze, while cost of materials grew a more moderate 9.2% YoY.
The stock went into the print at ₹1,685, down 10.9% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management targets sustained double-digit growth via balanced volume/price/mix with upward bias on premiumisation spend. Gross margins to remain 'in range'; EBITDA to absorb higher A&P (15.8%, up from 12-13%). No numeric FY27 revenue or PAT targets provided.
— This quarter: met
Against management's own prior guidance — sustained double-digit growth via volume/price/mix, margins absorbing higher A&P — this quarter is a clean match: growth delivered, and A&P ran even hotter than the 15.8% marker, so the compression reflects the plan playing out rather than a miss. No formal numeric consensus for this specific quarter turned up in public previews, so vsStreet is marked unknown; the broader brokerage tone (Goldman Sachs and Citi have held Sell ratings through 2026) has flagged exactly these margin and competitive-intensity concerns. It's also worth noting the YoY base is soft: Q2 FY26 PAT itself had fallen 17.1% YoY on GST-transition distributor disruption, so this year's +4.3% YoY sits on a depressed prior-year print. Alongside the results, the board declared a first interim dividend of ₹24/share (₹652.77 Cr aggregate, record date November 2, 2026), and separately the company saw a marketing leadership change — EVP-Marketing Gunjit Jain resigns effective November 30, succeeded by Akash Parekh from December 1 — landing just as A&P investment is being stepped up. No standalone press-release commentary from management was available in the filing to cross-check against the numbers.
W1
A&P intensity trajectory — guided to ~15.8% of revenue (from 12-13%); actual hit ~18.5% this quarter — watch whether Q3 FY27 holds near this level or normalizes down.
W2
Whether double-digit revenue growth (12.3% this quarter, 11.8% in Q1 FY27) sustains into H2 FY27 as the base normalizes from last year's GST-disruption-hit Q2 FY26.
W3
Leadership transition — new EVP-Marketing Akash Parekh takes over December 1, 2026, and MD&CEO Manish Anandani's formal appointment goes to shareholder postal ballot (cut-off October 23, 2026).
Standalone only — company has no subsidiary/JV (Note 7); single reportable segment 'Personal Care' so no segment breakout (Note 6); source figures in ₹ Lakh converted to Crore (÷100); no exceptional items this quarter or year-ago quarter (Nil both), so raw and underlying YoY PAT growth are identical.
Premium momentum carries into Q2—can Street's 10% growth thesis hold post-leadership handoff?
Colgate beat the Street by 500bp in Q1 with 12% sales growth fueled by premiumization. Q2 comes post-MD transition and against an easing ownership backdrop (FII -307bp YoY). What to watch: whether premium-portfolio momentum sustains, margin resilience holds, and guidance for H2 execution.
What to Expect
~₹1,610–1,640 Cr
Q1 delivered ₹1,591 Cr (12% YoY). Street consensus for FY27 full-year is 9.31% growth; Q2 likely tracking above that on premium traction.
~₹330–350 Cr
Q1 was ₹343 Cr (11% adjusted growth). Margin resilience and cost-control initiatives expected to offset any gross-margin headwind.
On uptrend
Visible White Purple, Colgate PerioGard (ISP-certified), and whitening variants driving category-outperformance. Watch for % of sales.
A strong print would show double-digit revenue growth (≥11%) with PAT above ₹340 Cr, plus color on premium-segment momentum in an inflationary quarter. A weak print would see growth slip below 8% or PAT below ₹320 Cr, signaling demand softness or margin compression that undercuts the premiumization thesis.
On Track?
Colgate opened FY27 with a 500bp beat—Q1's 12% growth vs. the Street's penciled 7–9% was a strong signal of pricing power and mix uplift. For the full year, consensus calls 9.31% sales growth (₹6.54k Cr) and 8.24% EPS growth (₹53.74). Q2 tracking above the full-year consensus would reinforce that the premium-led reacceleration is embedded, not a one-quarter pop. Conversely, a deceleration below Q1's pace would raise questions about demand elasticity and how much guidance the Street should grant.
What the Street Says
Since Last Quarter
1 · Leadership Transition
Prabha Narasimhan (MD & CEO through Sept 26) promoted externally to EVP. Manish Anandani took helm from Sept 27. Continuity of strategy and earnings momentum are early tests; prior market saw no operational disruption at the interim.
2 · EVP Legal Exit & Internal Audit Change
Priyan Pillay resigned (EVP Legal, eff Oct 23). G. Ramprasad (Internal Auditor) exited Aug 31. Routine governance adjustments; no red flags flagged in filings.
3 · Premium Portfolio Seals
Colgate PerioGard received Indian Society of Periodontology (ISP) Seal in Aug, reinforcing clinical credibility of the gum-care regimen. Colgate Visible White Purple continues to drive mix.
4 · Oral Health Awareness Push
Largest Multi-Location Oral Screening Program (3.08 lakh students in 10 days, Tamil Nadu/Puducherry) in Sept. KBC Season 18 partnership for brand amplification. Marketing spend elevated; ensure Q2 guidance flags full-year ad-spend trajectory.
5 · Ownership Pressure
FII stake down 307bp YoY to 13.59% (Q1 FY27 vs Q2 FY26's 20.39%). DII +311bp to 15.82%. Stock down -22.6% from ₹2,301.6 ATH; broad FMCG selloff + valuation reset. Watch for FII commentary on pricing/growth sustainability on Q2 call.
What to Watch on Result Day
1 · Premium Mix & Underlying Growth
Expect color on Visible White Purple, PerioGard, and whitening-category performance as % of revenue. Did premiumization hold pace with Q1's momentum, or is mix helping mask slower base-volume growth? This will define Street's conviction on the FY27 thesis.
2 · Margin Trajectory & H2 Outlook
Q1 saw adjusted profit growth at +11% (vs revenue +12%), implying slight margin compression. Q2 will signal whether cost-control and/or price realization are holding the line. H2 forward guidance—especially on gross-margin trends and ad-spend—will be critical for FY27 PAT tracking.
3 · Guidance Reaffirmation & FII Sentiment
New MD Manish Anandani's first quarter-end results call will anchor investor confidence in continuity. Any pullback in FY27 growth assumptions, or commentary on demand softness, could trigger further FII outflows. A reaffirmed or raised H2 outlook would support the premium-growth story and defend valuation.
Colgate-Palmolive India's Q1 beat reset expectations upward, but the stock remains 22.6% off its May ATH as FII sentiment soured on broad FMCG headwinds and valuation caution. Q2 will tell us whether double-digit growth is the new run-rate or a statistical bounce on a benign base. The premium-portfolio narrative is strong—Visible White Purple, PerioGard's ISP seal, and margin discipline are all live. The risk: elasticity cracks if consumer trade-down accelerates, or if cost inflation forces margin concessions. With a new MD at the helm post-Sept 27, execution continuity and credible H2 guidance will matter as much as the headline print.